ID   LNCaP C4-2B
AC   CVCL_4784
SY   C4-2B; C4-2 B; C4-2 Bone metastatic
DR   BTO; BTO:0004959
DR   EFO; EFO_0006365
DR   ATCC; CRL-3315
DR   Cosmic; 1689709
DR   ENCODE; ENCBS002MOV
DR   ENCODE; ENCBS108UKE
DR   ENCODE; ENCBS109FVF
DR   ENCODE; ENCBS159HRH
DR   ENCODE; ENCBS328CYG
DR   ENCODE; ENCBS391IVJ
DR   ENCODE; ENCBS440KYC
DR   ENCODE; ENCBS582KTC
DR   ENCODE; ENCBS728XMM
DR   ENCODE; ENCBS947VNK
DR   GEO; GSM648816
DR   Progenetix; CVCL_4784
DR   Wikidata; Q54902815
RX   PubMed=8168083;
RX   PubMed=15162376;
RX   PubMed=24587179;
RX   PubMed=33298586;
WW   https://en.wikipedia.org/wiki/LNCaP
CC   Characteristics: Bone metastatic.
CC   Doubling time: 24-36 hours (ATCC).
CC   Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line).
CC   Omics: Deep exome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Derived from metastatic site: Left supraclavicular lymph node.
ST   Source(s): ATCC
ST   Amelogenin: X,Y
ST   CSF1PO: 9,10,11
ST   D13S317: 10,11
ST   D16S539: 10,11
ST   D5S818: 11,12
ST   D7S820: 8.1,9.1,10.3
ST   TH01: 9
ST   TPOX: 8,9
ST   vWA: 16,18
DI   NCIt; C4863; Prostate carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens
HI   CVCL_4782 ! LNCaP C4-2
SX   Male
AG   50Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 20-05-21; Version: 22
//
RX   PubMed=8168083;
RA   Thalmann G.N., Anezinis P.E., Chang S.-M., Zhau H.E., Kim E.E.,
RA   Hopwood V.L., Pathak S., von Eschenbach A.C., Chung L.W.K.;
RT   "Androgen-independent cancer progression and bone metastasis in the
RT   LNCaP model of human prostate cancer.";
RL   Cancer Res. 54:2577-2581(1994).
//
RX   PubMed=15162376; DOI=10.1002/pros.20031;
RA   Liu A.Y., Brubaker K.D., Goo Y.A., Quinn J.E., Kral S., Sorensen C.M.,
RA   Vessella R.L., Belldegrun A.S., Hood L.E.;
RT   "Lineage relationship between LNCaP and LNCaP-derived prostate cancer
RT   cell lines.";
RL   Prostate 60:98-108(2004).
//
RX   PubMed=24587179; DOI=10.1371/journal.pone.0090002;
RA   Spans L., Helsen C., Clinckemalie L., Van den Broeck T., Prekovic S.,
RA   Joniau S., Lerut E., Claessens F.;
RT   "Comparative genomic and transcriptomic analyses of LNCaP and C4-2B
RT   prostate cancer cell lines.";
RL   PLoS ONE 9:E90002-E90002(2014).
//
RX   PubMed=33298586; DOI=10.1158/1535-7163.MCT-20-0244;
RA   Kohrt S.E., Awadallah W.N., Phillips R.A. III, Case T.C., Jin R.-J.,
RA   Nanda J.S., Yu X.-P., Clark P.E., Yi Y.-J., Matusik R.J.,
RA   Anderson P.D., Grabowska M.M.;
RT   "Identification of genes required for enzalutamide resistance in
RT   castration-resistant prostate cancer cells in vitro.";
RL   Mol. Cancer Ther. 20:398-409(2021).
//